Lipid mediators in the pathophysiology of critical illness

Critical Care Medicine

Volumn 28, Issue 4 SUPPL., 2000, Pages

  Bulger, Eileen M ^a   Maier, Ronald V ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute respiratory distress syndrome; Cyclooxygenase; Eicosanoids; Inflammation; Leukotrienes; Lipid mediators; Lipoxygenase; Multiple organ failure syndrome; Omega 3 fatty acids; Platelet activating factor; Prostaglandins; Systemic inflammatory response syndrome; Thromboxane

Indexed keywords

HYDROXYICOSATETRAENOIC ACID; ICOSANOID; LEUKOTRIENE; MEMBRANE PHOSPHOLIPID; PROSTAGLANDIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE;

CELL MEMBRANE; CRITICAL ILLNESS; HUMAN; LIPID COMPOSITION; MEDIATOR RELEASE; NONHUMAN; NUTRITION; PATHOPHYSIOLOGY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0034018762     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200004001-00004     Document Type: Review

References (130)

1. Bone RC: Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 1992; 268: 3452-3455
2. Palombo JD, Lydon EE, Chen P L, et al: Fatty acid composition of lung, macrophage and surfactant phospholipids after short-term enteral feeding with n-3 lipids. Lipids 1994; 29:643-649
3. Freeman BA, Lynn WS: Fatty acid secretion and metabolism in "activated" rabbit alveolar macrophages. Biochim Biophys Acta 1980; 620:528-537
4. Morrow J, Awad J, Kato T, et al: Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 1992; 90: 2502-2507
5. 2 in inflammatory diseases. Clin Chem 1993; 39: 2453-2459
6. 2 in intensive care patients with peritonitis, multiple injury, and necrotizing pancreatitis. Klin Wochenschr 1989; 67:217-221
7. 2 in patients with multiple injuries. J Trauma 1990; 30: 1285-1290
8. 2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Can J Physiol Pharmacol 1983; 61:561-566
9. 2 expression and pathogenesis of the sepsis syndrome. Circ Shock 1993; 39:160-167
10. 2 in sera of febrile patients with microbiologically or clinically documented infections. Clin Infect Dis 1993; 17: 864-870
11. 2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid. FEBS Lett 1990; 273:23-26
12. 2 activity from rat vascular smooth muscle cells mediated by cAMP. Eur J Biochem 1989; 181:237-242
13. 2 axis following I.V. endotoxin challenge in human volunteers. FASEB J 1990; 4:A1714
14. 2 levels with circulatory collapse. Crit Care Med 1988; 16:1-7
15. Holm BA, Keicher L, Liu MY, et al: Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 1991; 71: 317-321
16. 2 levels: Correlation with the hemodynamic and pulmonary changes in Gram-negative septic shock. J Lab Clin Med 1984; 104: 873-881
17. 2. Inflammation 1986; 10:183-193
18. Offenstadt G, Pinta P, Masliah J, et al: Phospholipase and prophospholipasic activities in bronchoalveolar lavage fluid in severe acute pulmonary disease with or without ARDS. Intensive Care Med 1981; 7:285-290
19. 2 via GTP-binding proteins: Arachidonic acid and its metabolites as second messengers. Trends Neurosci 1988; 11:117-123
20. 2 in rat renal mesangial cells. J Biol Chem 1988; 263:16645-16651
21. 2 regulates critical inflammatory mediators of multiple organ failure. J Surg Res 1994; 56:199-205
22. 2 in pulmonary endothelium. Am J Physiol 1989; 257:L430
23. 2: Basic and Clinical Aspects in Inflammatory Diseases. Uhl W, Nevalainen TJ, Buchler MW (Eds). Vol 24. Basel, Karger, 1997, pp 117-122
24. 2. Abstr. In: Second International Congress on the Immune Consequences of Trauma, Shock, and Sepsis: Mechanisms and Therapeutic Approaches, Munich, Germany, 1991
25. 2: A new target for monoclonal antibody therapy in sepsis. Abstr. In: Second International Congress on the Immune Consequences of Trauma, Shock, and Sepsis: Mechanisms and Therapeutic Approaches. Munich, Germany, 1991
26. 2 inhibition decouples lung injury from gut ischemia-reperfusion. Surgery 1992; 112:173-180
27. 2 by quercetin. Inflammation 1993; 17:573-582
28. 2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. J Pharmacol Exp Ther 1995; 274: 1254-1262
29. 2 production in vivo of the macrophage-like P388D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide. J Biol Chem 1989; 264:8520-8528
30. Alexander JW: Immunonutrition: The role of omega-3 fatty acids. Nutrition 1998; 14: 627-633
31. Calder PC: n-3 polyunsaturated fatty acids and cytokine production in health and disease. Ann Nutr Metab 1997; 41:203-234
32. 2 production in a rat model of chronic sepsis. J Trauma 1991; 31:768-773
33. Johnson JAd, Griswold JA, Muakkassa FF: Essential fatty acids influence survival in sepsis. J Trauma 1993; 35:128-131
34. Cook JA, Wise WC, Butler RR, et al: The potential role of thromboxane and prostacyclin in endotoxic and septic shock. Am J Emerg Med 1984; 2:28-37
35. Endres S, Ghorbani R, Kelley VE, et al: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320:265-271
36. Meydani SN, Endres S, Woods MM, et al: Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: Comparison between young and older women. J Nutr 1991; 121: 547-555
37. Meydani SN, Lichtenstein AH, Cornwall S, et al: Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. J Clin Invest 1993; 92:105-113
38. Virella G, Fourspring K, Hyman B, et al: Immunosuppressive effects of fish oil in normal human volunteers: Correlation with the in vitro effects of eicosapentanoic acid on human lymphocytes. Clin Immunol Immunopathol 1991; 61:161-176
39. Gottschlich MM, Jenkins M, Warden GD, et al: Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN 1990; 14: 225-236
40. Bower RH, Cerra FB, Bershadsky B, et al: Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: Results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995; 23:436-449
41. Moore FA, Moore EE, Kudsk KA, et al: Clinical benefits of an immune-enhancing diet for early postinjury enteral feeding. J Trauma 1994; 37:607-615
42. Kudsk KA, Minard G, Croce MA, et al: A randomized trial of isonitrogenous enteral diets after severe trauma. An immune-enhancing diet reduces septic complications. Arm Surg 1996; 224:531-540
43. Atkinson S, Sieffert E, Bihari D: A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill. Guy's Hospital Intensive Care Group. Crit Care Med 1998; 26: 1164-1172
44. Mendez C, Jurkovich GJ, Garcia I, et al: Effects of an immune-enhancing diet in critically injured patients. J Trauma 1997; 42:933-940
45. Gadek JE, DeMichele SJ, Karlstad MD, et al: Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral nutrition in ARDS Study Group. Crit Care Med 1999; 27:1409-1420
46. Fink MP: Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis. J Antimicrob Chemother 1998; 41(Suppl A):81-94
47. Versteeg HH, van Bergen en Henegouwen PM, van Deventer SJ, et al: Cyclooxygenase-dependent signalling: Molecular events and consequences. FEBS Lett 1999; 445:1-5
48. 2 mediates lipopolysaccharide-induced macrophage procoagulant activity by a cyclic adenosine monophosphate-dependent pathway. Surgery 1993; 114:314-323
49. 2, cholera toxin and 8 bromo-cyclic AMP on lipopolysaccharide-induced gene expression of cytokines in human macrophages. Immunology 1995; 84:446-452
50. Petrak RA, Balk RA, Bone RC: Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin 1989; 5:303-314
51. 2 increase in rats with peritonitis due to cecal ligation. Circ Shock 1985; 16:297-305
52. Feuerstein N, Ramwell PW: In vivo and in vitro effects of endotoxin on prostaglandin release from rat lung. Br J Pharmacol 1981; 73:511-516
53. Slotman GJ, Quinn JV, Burchard KW, et al: Thromboxane, prostacyclin, and the hemodynamic effects of graded bacteremic shock. Circ Shock 1985; 16:395-404
54. Goldblum SE, Wu KM, Tai HH: Streptococcus pneumoniae-induced alterations in levels of circulating thromboxane and prostacyclin: Dissociation from granulocytopenia, thrombocytopenia, and pulmonary leukostasis. J Infect Dis 1986; 153:71-77
55. Oettinger W, Berger D, Beger HG: The clinical significance of prostaglandins and thromboxane as mediators of septic shock. Klin Wochenschr 1987; 65:61-68
56. Ball HA, Cook JA, Wise WC, et al: Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock. Intensive Care Med 1986; 12:116-126
57. Jaffe BM, LaRosa CA, Kimura K: Prostaglandins and surgical diseases: Part II. Curr Probl Surg 1988; 25:711-747
58. Reines HD, Halushka PV, Cook JA, et al: Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 1982; 2:174-175
59. 2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991; 144:1095-1101
60. Deby-Dupont G, Braun M, Lamy M, et al: Thromboxane and prostacyclin release in adult respiratory distress syndrome. Intensive Care Med 1987; 13:167-174
61. Lefer AM: Eicosanoids as mediators of ischemia and shock. Fed Proc 1985; 44:275-280
62. Feuerstein G, Jimerson DC, Kopin IJ: Prostaglandins, catecholamines, and cardiovascular responses to hemorrhage. Am J Physiol 1981; 240:R166-R174
63. Feuerstein G, Zerbe RL, Meyer DK, et al: Alteration of cardiovascular, neurogenic, and humoral responses to acute hypovolemic hypotension by administered prostacyclin. J Cardiovasc Pharmacol 1982; 4:246-253
64. Krausz MM, Utsunomiya T, Feuerstein G, et al: Prostacyclin reversal of lethal endotoxemia in dogs. J Clin Invest 1981; 67: 1118-1125
65. 1) after hemorrhagic shock. Adv Shock Res 1982; 8:171-176
66. 1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Ann Surg 1986; 203:371-378
67. 1 Study Group. Chest 1989; 96:114-119
68. 1 in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1996; 24:10-15
69. 2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:1671-1677
70. Liu SF, Newton R, Evans TW, et al: Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci (Colch) 1996; 90:301-306
71. Chan CC, Boyce S, Brideau C, et al: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995; 274:1531-1537
72. Smith WL, DeWitt DL: Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15: 179-194
73. Hempel SL, Monick MM, Hunninghake GW: Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 1994; 93:391-396
74. 2 synthesis by human lung fibroblasts. Am J Respir Cell Mol Biol 1995; 12:358-365
75. Mitchell JA, Belvisi MG, Akarasereenont P, et al: Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 1994; 113:1008-1014
76. Moatter T, Gerritsen ME: Fibroblast growth factor upregulates PGG/H synthase in rabbit microvascular endothelial cells by a glucocorticoid independent mechanism. J Cell Physiol 1992; 151:571-578
77. Chen B, Chen Y, Lin W: Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology 1999; 97:124-129
78. Dean JL, Brook M, Clark AR, et al: p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999; 274: 264-269
79. Arbabi S, Rosengart MR, Garcia I, et al: Hyperosmotic-induced cyclooxygenase espression and prostacyclin production: Interactions of protein kinase pathways and actin cytoskeleton. J Clin Invest 1999; Submitted for Publication
80. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912-918
81. Arons MM, Wheeler AP, Bernard GR, et al: Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 1999; 27:699-707
82. Makhlouf MA, Cook JA, Halushka PV: Fatty acids and prostaglandins as mediators of the septic response. In: Sepsis and Multiple Organ Failure. Fein AM, Abraham EM, Balk RA (Eds). Baltimore, Williams & Wilkins, 1997, pp 116-123
83. Leeman M, Boeynaems JM, Degaute JP, et al: Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome. Chest 1985; 87:726-730
84. Reines HD, Halushka PV, Olanoff LS, et al: Dazoxiben in human sepsis and adult respiratory distress syndrome. Clin Pharmacol Ther 1985; 37:391-395
85. Williams JC, Maier RV: Ketoconazole inhibits alveolar macrophage production of inflammatory mediators involved in acute lung injury (adult respiratory distress syndrome). Surgery 1992; 112:270-277
86. Slotman GJ, Burchard KW, D'Arezzo A, et al: Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 1988; 28:648-654
87. Yu M, Tomasa G: A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21: 1635-1642
88. Steinberg KP, Maier RV, Schoenfeld D, et al: A randomized placebo controlled trial of ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome. JAMA, In Press
89. Sprague RS, Stephenson AH, Dahms TE, et al: Proposed role for leukotrienes in the pathophysiology of multiple systems organ failure. Crit Care Clin 1989; 5:315-329
90. Feinmark SJ: Cooperative synthesis of leukotrienes by leukocytes and vascular cells. Ann N Y Acad Sci 1988; 524:122-132
91. 4 in the pulmonary vascular bed. Circ Res 1984; 55:707-717
92. 4 affects pulmonary and cardiovascular dynamics in monkey. Nature 1982; 295:327-329
93. Woodward DF, Weichman BM, Gill CA, et al: The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 1983; 25:131-142
94. Stephenson AH, Lonigro AJ, Hyers TM, et al: Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am Rev Respir Dis 1988; 138:714-719
95. Ogata M, Matsumoto T, Kamochi M, et al: Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pre-treated mice. Infect Immun 1992; 60: 2432-2437
96. Yoshikawa D, Goto F: Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: Role of the leukocyte. Circ Shock 1992; 38:29-33
97. Coggeshall JW, Christman BW, Lefferts PL, et al: Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxemia in sheep. J Appl Physiol 1988; 65:1351-1359
98. Kuratomi Y, Lefferts PL, Christman BW, et al: Effect of a 5-lipoxygenase inhibitor on endotoxin-induced pulmonary dysfunction in awake sheep. J Appl Physiol 1993; 74: 596-605
99. Ahmed T, Wasserman MA, Muccitelli R, et al: Endotoxin-induced changes in pulmonary hemodynamics and respiratory mechanics. Role of lipoxygenase and cyclooxygenase products. Am Rev Respir Dis 1986; 134:1149-1157
100. 4-receptor antagonist in endotoxin shock: A prospective, controlled trial in a porcine model. Crit Care Med 1993; 21:1825-1837
101. 4 receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs. Surgery 1993; 114:191-198
102. 4. J Appl Physiol 1995; 78:1121-1131
103. Serhan CN, Samuelsson B: Lipoxins: A new series of eicosanoids (biosynthesis, stereo-chemistry, and biological activities). Adv Exp Med Biol 1988; 229:1-14
104. Braquet P, Hosford D, Koltz P, et al: Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins. Lipids 1991; 26: 1071-1075
105. Maier RV, Hahnel GB, Fletcher JR: Platelet-activating factor augments tumor necrosis factor and procoagulant activity. J Surg Res 1992; 52:258-164
106. Floch A, Bousseau A, Hetier E, et al: RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. J Lipid Mediat 1989; 1:349-360
107. Poubelle PE, Gingras D, Demers C, et al: Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes. Immunology 1991; 72:181-187
108. Thivierge M, Rola-Pleszczynski M: Upregulation of inducible cyclooxygenase gene expression by platelet-activating factor in activated rat alveolar macrophages. J Immunol 1995; 154:6593-6599
109. Tetta C, Mariano F, Buades J, et al: Relevance of platelet-activating factor in inflammation and sepsis: Mechanisms and kinetics of removal in extracorporeal treatments. Am J Kidney Dis 1997; 30:S57-S65
110. Bussolino F, Camussi G, Aglietta M, et al: Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol 1987; 139: 2439-2446
111. Mathiak G, Szewczyk D, Abdullah F, et al: Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 1997; 7:391-404
112. Olson NC, Joyce PB, Fleisher LN: Role of platelet-activating factor and eicosanoids during endotoxin-induced lung injury in pigs. Am J Physiol 1990; 258:H1674-H1686
113. Siebeck M, Weipert J, Keser C, et al: A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. J Trauma 1991; 31:942-950
114. Tolins JP, Vercellotti GM, Wilkowske M, et al: Role of platelet activating factor in endotoxemic acute renal failure in the male rat. J Lab Clin Med 1989; 113:316-324
115. Wallace JL, Whittle BJ: Prevention of endotoxin-induced gastrointestinal damage by CV-3988, an antagonist of platelet-activating factor. Eur J Pharmacol 1986; 124: 209-210
116. Wallace JL, Steel G, Whittle BJ, et al: Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. Gastroenterology 1987; 93:765-773
117. Thompson WA, Coyle S, Van Zee K, et al: The metabolic effects of platelet-activating factor antagonism in endotoxemic man. Arch Surg 1994; 129:72-79
118. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994; 22:1720-1728
119. Froon AM, Greve JW, Buurman WA, et al: Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: A prospective, multi-center, double-blind, randomized phase II trial. Shock 1996; 5:313-319
120. Tjoelker LW, Wilder C, Eberhardt C, et al: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374:549-553
121. Hofbauer B, Saluja AK, Bhatia M, et al: Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis. Gastroenterology 1998; 115:1238-1247
122. Caplan MS, Lickerman M, Adler L, et al: The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis. Pediatr Res 1997; 42:779-783
123. Partrick DA, Moore EE, Moore FA, et al: Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure. Shock 1997; 7:170-174
124. Pribble J, Yu A, Peterman G: Evaluations of the safety, pharmacokinetics, and clinical pharmacology of recombinant human platelet activating factor acetylhydrolase (rPAF-AH) in healthy subjects and critically ill patients. Abstr. Presented at the 6th International Congress on PAF and Related Lipid Mediators, New Orleans, LA, 1998
125. Graber , Sumida C, Nunez EA: Fatty acids and cell signal transduction. J Lipid Mediat Cell Signal 1994; 9:91-116
126. Corado J, Le Deist F, Griscelli C, et al: Inositol 1,4,5-trisphosphate- and arachidonic acid-induced calcium mobilization in T and B lymphocytes. Cell Immunol 1990; 126:245-254
127. Abramson SB, Leszczynska-Piziak J, Weissmann G: Arachidonic acid as a second messenger. Interactions with a GTP-binding protein of human neutrophils. J Immunol 1991; 147:231-236
128. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-665
129. Bursten S, Weeks R, West J, et al: Potential role for phosphatidic acid in mediating the inflammatory responses to TNF alpha and IL-1 beta. Circ Shock 1994; 44:14-29
130. Hannun YA, Bell RM: Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 1989; 243:500-507